• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo
- - - - -

Mass Spectrometry Biomarker Research


  • Please log in to reply
No replies to this topic

#1 maestro949

  • Guest
  • 2,350 posts
  • 4
  • Location:Rhode Island, USA

Posted 17 November 2006 - 12:36 PM


Mass Spectromety seems to be the best way to look for biomarkers. Here's an article indicating that Mass Spectrometry in Biomarker Research to Exceed $745 Million by 2010. The article links to a Market Research report. The report costs $3k but the table of contents is accessible after signing up. There is only 1 bullet on aging but overall the TOC alone provides some insight into the market concepts, terms, companies and products.

Chapter One: Executive Summary

    * Proteomics Tools, Approaches in Drug Discovery, Biomarker Discovery
    * Biomarker Validation, Diagnostics, Prognostics
    * Sources of Samples
    * Biomarkers in Pharmaceutical Industry, Diagnostics Industry
    * Drug Discovery and Development
    * Diagnostics
    * Scope and Outline
    * Market Summary

Chapter Two: Introduction

    * Historical Background
    * Definitions
          o Biomarkers
          o Screening Markers
          o Prognostic Markers
          o Staging Markers
          o Stratification Markers
          o Efficacy Markers
          o Target Markers
          o Toxicity Markers
          o Antecedent Markers
          o Translation Markers
          o Surrogate Markers
          o Positive Predictive Value (PPV)
          o Sensitivity
          o Specificity

    * Value of Biomarkers in Industry
    * Mass Spectrometry in Proteomics
          o Software
          o Tandem Mass Spectrometry
          o Types of Mass Spectrometers Used for Protein Biomarkers
          o MALDI-TOF
          o TOF / TOF
          o Triple Quad
          o Quadrupole TOF
          o Quadrupole Ion Trap
          o Fourier Transform MS (FTMS / FT-ICR-MS)

    * Biomarker Discovery
          o MS in Biomarker Applications
          o Biomarker Discovery Process in Diagnostics
          o Biomarker Discovery in Drug Development

    * Biomarker Validation
          o Validation Process in Drug Discovery and Development
          o Validation Process in Diagnostics

Chapter Three: Disease Application Areas

    * Cancer
          o Prostate
          o Prostate Cancer Related Articles:
          o Breast
          o Breast Cancer Related Articles:
          o Lung
          o Ovarian / Endometrial
          o Ovarian Cancer Related Articles:
          o Oral / Lymphoma
          o Oral Cancer Related Articles:
          o Liver
          o Other / Multiple Cancers
          o General Cancer Related Articles:

    * Cardiovascular Disease
    * Neurological Disease
          o Parkinson’s Disease
          o Alcohol Abuse
          o Sleep Apnea
          o Cerebral Injury
          o Amyotrophic Lateral Sclerosis (ALS)

    * Diabetes
    * Aging
          o Aging Related Articles:

    * Sepsis

Chapter Four: Proteomics Tools

    * Introduction
    * 2D Gel Electrophoresis (2DGE)
    * Recent Developments in 2DGE
    * Liquid Chromatography (LC)
    * Recent Developments in LC
    * Protein Chips

Chapter Five: Trends

    * Industry Trends
          o MS Vendors Creating Biomarker Divisions, Collaborations
          o Some Acquisition, Consolidation Trends in Recent Years
          o Regulatory Environment Becoming More Clearly Defined
          o Drug Companies’ Woes Bringing Growth in Biomarkers
          o Intellectual Property Defines Companies’ and Instruments’ Territories
          o Diagnostics Industry Facing Uncertain IP Issues
          o Globalization and Diversity Converging Rapidly
          o Technology Trends
                + Ongoing Debate, Confusion Over Protein Patterns Vs Identified Markers
                + Emphasis on Sample Preparation, Fractionation
                + High Abundance, Low Abundance, Both
                + LC and ESI Approaches Growing Relative To 2DGE and MALDI
                + New Combinations of LC, ESI, and MALDI
                + Integration and Automation
                + Advances in Labels to Address Focused Applications
                + Biomarkers for Classes of Drugs
                + Chemogenomics / Chemoproteomics Techniques Further Driving Advances
                + Direct Analysis of Tissue
                + Shift to Solid-State Lasers
                + Field Applications Driving Miniaturization

Chapter Six: MS Software Market

    * Products and Competitors
          o Agilent Technologies
          o GeneSpring MS
          o MassHunter
          o SpectrumMill
          o Applied Biosystems / MDS Sciex
          o Analyst
          o MarkerView
          o Pro QUANT
          o ProteinPilot
          o Bruker Biosciences
          o ClinProTools
          o flexImaging
          o Cerno Biosciences
          o MassWorks
          o Correlogic Systems
          o Proteome Quest
          o GeneData AG
          o Expressionist Pro
          o GenoLogics Life Sciences Software
          o Proteus
          o Insightful Corp
          o S+Proteome
          o Genstruct
          o Molecular Epistemics platform
          o Matrix Science
          o Mascot
          o Nonlinear Dynamics
          o Progenesis PG600
          o Thermo
          o SIEVE
          o Public Domain Tools and Databases

    * Revenue and Growth Forecast

Chapter Seven: MS Services Market

    * Competitors
          o BG Medicine
          o Biophysical Corporation
          o Caprion Pharmaceuticals
          o Celera Diagnostics
          o Compugen
          o Panatecs
          o Power3 Medical Products
          o Predictive Diagnostics
          o Protein Discovery, Inc
          o RxGen PrimaTox
          o SurroMed

    * Revenue and Growth Forecast

Chapter Eight: MS Instrumentation Market

    * Products
          o Agilent Technologies (Palo Alto, CA)
          o Agilent 1200 Series HPLC-Chip/MS System
          o Agilent 3100 OFFGEL Fractionator
          o Agilent 6210 TOF
          o Agilent 6340 Ion Trap Liquid Chromatograph/Mass Spectrometer (LC/MS)
          o Agilent 6510 Q-TOF LC/MS
          o Multiple Affinity Removal System 7 LC Column and Spin Tube
          o Applied Biosystems / MDS Sciex (Foster City, CA ; Ontario, Canada)
          o 3200 Q TRAP LC/MS/MS System for Proteomics Applications
          o 4000 Q TRAP LC/MS/MS System for Proteomics Applications
          o 4800 MALDI-TOF/TOF
          o ICAT Reagents
          o iTRAQ Reagents
          o QSTAR Elite LC/MS/MS
          o MIDAS TRAQ Systems
          o Becton Dickinson (Franklin Lakes, NJ)
          o P100 Sample Collection Tubes
          o Beckman Coulter (Fullerton, CA)
          o ProteomeLab IgY-12 Partitioning Chemistries
          o Bruker Biosciences (Billerica, MA)
          o apex-Qe
          o autoflex II, autoflex II TOF/TOF
          o ClinProt Large-Protein Beads
          o ClinProt Micro
          o ClinProtRobot
          o Isotope Coded Protein Labels (ICPL) Triplex Kit
          o MALDI Molecular Imager
          o microflex, microflex LT
          o Protein Post-Translational Modification (PTM) Discovery Tool
          o ultraflex, ultraflex TOF/TOF
          o Expression Pathology (Gaithersburg, MD)
          o Liquid Tissue MS Protein Prep Kit
          o PerkinElmer (Wellesley, MA)
          o prOTOF 2000 MALDI O-TOF
          o Qiagen (Venlo, The Netherlands)
          o MSXpress Protein Chip
          o Shimadzu / Kratos (Kyoto, Japan)
          o LCMS-IT-TOF
          o Thermo Electron (Waltham, MA)
          o LTQ XL
          o LTQ FT
          o LTQ Orbitrap
          o MDLC LTQ LC-MS
          o Waters (Milford, MA)
          o LCT Premier XE
          o micro MX
          o Protein Expression System
          o Q-Tof Premier

    * Total Market Size and Growth Forecast
    * The Market by Disease Area
    * Competitive Analysis: Market Share by Vendor
    * Market Share by Product Type

Chapter Nine: Consortia and Alliances

    * The Biomarker Alliance
    * Biomarkers Research Initiatives in Mass Spectrometry (BRIMS)
    * Clinical Proteomic Technologies Initiative for Cancer
    * Clinical Plasma Profiling Consortium
    * Early Detection Research Network (EDRN)
    * HUPO Plasma Proteome Project
    * Oncology Biomarker Qualification Initiative (OBQI)
    * Pharmacogenomics Research Network (PGRN)
    * Predictive Safety Testing Consortium

Chapter Ten: Company Profiles

    * Agilent Technologies (Palo Alto, CA)
    * Applied Biosystems / MDS Sciex (Foster City, CA ; Ontario, Canada)
    * Bruker BioSciences (Billerica, MA)
    * Ciphergen Biosystems (Fremont, CA) (Bio-Rad)
    * GE Healthcare Bio-Sciences (Little Chalfont, United Kingdom) -
    * formerly Amersham Biosciences (Uppsala, Sweden)
    * PerkinElmer (Wellesley, MA)
    * Thermo Electron (Waltham, MA)
    * Waters (Milford, MA)

Chapter Eleven: Deals
Chapter Twelve: Academic / Government / Non-Profit Research

    * The Center for Biomarker Research
    * Johns Hopkins Center for Biomarker Discovery
    * Plasma Proteome Institute

Chapter Thirteen: Competitive or Disruptive Technologies

    * Protein Arrays, Chips
          o Invitrogen ProtoArray
          o Protneteomix Protein, Peptide and Antibody Arrays
          o Whatman Schleicher & Schuell Serum Biomarker Chip
          o Array of Micromachined Ultra Sonic Electrospray (AMUSE)
          o Monogram Biosciences’ (formerly Aclara) eTag Technology
          o Imaging-Based Techniques
          o ELISA

Chapter Fourteen: Challenges

    * Debate Over Serum Proteomics and Biomarkers
    * Advances in Competing, Complementary Techniques, Software Erode Sales
    * Reproducibility is Key Priority But Elusive
    * Clinical Research Not Yet Experienced With Biomarkers, Procedures
    * Blockbuster Mentality Creates Obstacles for Biomarkers
    * Gap Between Pharmaceuticals and Diagnostics Still Wide
    * Large Investment Required for Biomarker Validation Creates Gap
    * Dropping Prices Hurt Revenues, Confuse Customers
    * Regulatory and Ethical Issues Not Completely Resolved
    * Feasibility of Biomarker Approaches Still Unproven
    * Data Analysis Bottleneck Slows Momentum

Chapter Fifteen: Strategic Recommendations

    * Recommendation 1: Software
    * Recommendation 2: Consumables
    * Recommendation 3: Standards, Quality, and Data Exchange
    * Recommendation 4: Reliability and User-Friendliness
    * Recommendation 5: Systems Biology
    * Recommendation 6: Partnering for Novel Technologies
    * Recommendation 7: Drug and Diagnostics Partnerships
    * Recommendation 8: Training and Education

List of Exhibits

Chapter One: Executive Summary

    * Figure 1-1: Market Summary: MS for Protein Biomarker Applications 2005-2011

Chapter Six: MS Software Market

    * Table 6-1: The World Market for Protein Biomarker MS Software (Revenues) 2005-2011
    * Figure 6-1: Trending in the Revenues for Protein Biomarker MS Software 2005-2011
    * Table 6-2: The World Market for Protein Biomarker MS Software (Growth) 2005-2011
    * Figure 6-2: Trending in the Growth of Protein Biomarker MS Software 2005-2011

Chapter Seven: MS Services Market

    * Table 7-1: The World Market for Protein Biomarker Services (Revenues) 2005-2011
    * Figure 7-1: Trending in the Revenues for Protein Biomarker Services 2005-2011
    * Table 7-2: The World Market for Protein Biomarker Services (Growth) 2006-2011
    * Figure 7-2: Trending in the Growth of Protein Biomarker Services 2006-2011

Chapter Eight: MS Instrumentation Market

    * Table 8-1: The World Market for MS Instruments for Protein Biomarker Applications (Revenues) 2005-2011
    * Figure 8-1: Trending in the Revenues for MS Instruments for Protein Biomarker Applications 2005-2011
    * Table 8-2: The World Market for MS Instruments for Protein Biomarker Applications (Growth) 2006-2011
    * Figure 8-2: Trending in the Growth of MS Instruments for Protein Biomarker Applications 2006-2011
    * Table 8-3: Protein Biomarker MS Revenues and Market Share by Disease Area 2005
    * Figure 8-3: Protein Biomarker MS Market Share by Disease Area 2005
    * Table 8-4: Protein Biomarker MS Revenues and Market Share by Leading Supplier 2005
    * Figure 8-4: Protein Biomarker MS Market Share by Leading Supplier 2005
    * Table 8-5: Protein Biomarker MS Revenues and Market Share by Product Type (Ion Trap, MALDI-TOF, Triple Quad, QqTOF, FTMS, Other, Service/Support) 2005
    * Figure 8-5: Protein Biomarker MS Market Share by Product Type 2005

Chapter Nine: Consortia and Alliances

    * Table 9-1: Early Detection Research Network (EDRN) Awardees (Institution, Organ Focus, Technology/Approach, Industry Collaboration)

Chapter Eleven: Deals

    * Table 11-1: Recent Deals, Collaborations, and Alliances






1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users